IFRX InflaRx: Forward P/S Multiple
The projected P/S multiple for InflaRx N.V. (IFRX) exhibits volatility, with the 386.20 level capturing the current state. This trend is driven by German laboratories and external antibody production. An outsourcing strategy for research minimizes capital expenditures while ensuring team flexibility. Prospects depend on the expansion of the drug Gohibic into intensive care units, although regulators are slowing the growth of the clinic network with post-audit requirements.
inflarx.de (IFRX) - metric breakdowns and financial figures
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- company liabilities and liquidity data:
- business earnings and investment ratios data:
IFRX - Final Profit|Expected Profit InflaRx N.V.|IFRX - Price to Earnings Multiple|Projected Price to Earnings InflaRx|IFRX - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio IFRX|IFRX - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months InflaRx|IFRX - Net earnings per share for the last four quarters|Quarterly EPS earnings growth inflarx.de|IFRX - Expected net earnings per share growth this year|Earnings growth forecast for next year InflaRx N.V.
- sales and revenue indicators:
Fundamental company analysis:IFRX (InflaRx GmbH)
InflaRx N.V. develops high-tech antibodies to prevent systemic immune destruction of organs, making its market capitalization dependent on commercialization forecasts. By analyzing the expected price-to-sales ratio, an investor assesses the current share price relative to future sales, determining the degree of optimism currently priced in and the resilience of the market valuation to potential corrections should growth rates shift.
Key competitors
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio ADMA Corp ADMA|Protagonist Therapeutics (PTGX) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue IMVT|KNSA (Kiniksa) - Forward P/S Multiple|Grifols SA - Future Price to Revenue|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|Price-to-Projected Revenue Ratio CLDX (Celldex Corp)|Forward P/S Multiple AUPH (Aurinia Pharmaceuticals)|Forward P/S Multiple biocryst.com BCRX|VERA - Price-to-Projected Revenue Ratio|Forward Price to Sales DNTH (Dianthus Therapeutics Inc)|PHVS (Pharvaris Corp) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue ABCL|Forward Price-to-Revenue Multiple TRML|PGEN: Forward Price to Sales|Price-to-Projected Revenue Ratio Pharming Group (PHAR)|Nektar Therapeutics Inc - Market Cap to Projected Revenue|Upstream Bio Corp - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Zenas Corp (ZBIO)|IMNM: Forward Price-to-Revenue Multiple|GOSS: Price-to-Projected Revenue Ratio|KALV (KalVista Pharmaceuticals, Inc.) - Forward Price-to-Revenue Multiple|SEPN - Market Cap to Expected Sales Ratio|PVLA (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|Savara Pharma (SVRA) - Market Cap to Expected Sales Ratio|Forward P/S Multiple RIGL|ANAB: Future Price to Revenue|Price-to-Projected Revenue Ratio Astria Therapeutics, Inc. ATXS|Forward Price to Sales ENGN|RAPT: Forward Price-to-Revenue Multiple|JBIO (Aerovate Therapeutics Inc) - Market Cap to Projected Revenue|Aclaris Therapeutics (ACRS) - Price-to-Projected Revenue Ratio|Future Price to Revenue KYTX (kyvernatx.com)|TLSA (Tiziana Life Sciences Ltd) - Forward P/S Multiple|CABA: Forward Price to Sales|Forward P/S Multiple VTYX|Forward P/S Multiple Theratechnologies, Inc (THTX)|Price-to-Projected Revenue Ratio Avalo Therapeutics, Inc AVTX|Forward Price to Sales ELDN|AGEN - Price-to-Projected Revenue Ratio|Climb Bio Inc. (CLYM) - Forward Price-to-Revenue Multiple|ZURA: Forward P/S Multiple|aTyr Pharmaceuticals (ATYR) - Forward P/S Multiple|Forward Price-to-Revenue Multiple ADAG|IMA: Forward Price to Sales|Forward P/S Multiple STTK|Market Cap to Expected Sales Ratio equilliumbio.com|Price-to-Projected Revenue Ratio Connect Biopharma Holdings Limited CNTB|IMUX - Forward Price-to-Revenue Multiple|ATRA - Price-to-Projected Revenue Ratio|x4pharma.com (XFOR) - Forward Price-to-Revenue Multiple|ACET (adicetbio.com) - Forward Price-to-Revenue Multiple|Celularity (CELU) - Forward P/S Multiple|Price-to-Projected Revenue Ratio INmune Bio Corp|Market Cap to Projected Revenue BRNS (Barinthus Biotherapeutics Corp)|Forward P/S Multiple KZR|SABS - Market Cap to Future Revenue Ratio|Forward P/S Multiple AKTX (Akari Therapeutics Plc)|Market Cap to Expected Sales Ratio Enlivex Therapeutics Ltd (ENLV)|QTTB - Price-to-Projected Revenue Ratio|GOVX (GeoVax Corp) - Market Cap to Projected Revenue|EDSA: Forward P/S Multiple|Future Price to Revenue IBIO (ibioinc.com)|Price-to-Projected Revenue Ratio Carisma Therapeutics Inc|Price-to-Projected Revenue Ratio XTLB|Forward P/S Multiple BOLT|Forward P/S Multiple hcwbiologics.com (HCWB)|Price-to-Projected Revenue Ratio Aptevo Therapeutics Inc. APVO|Forward Price to Sales AIM|ADTX: Forward Price-to-Revenue Multiple|GRI (GRI Bio Inc) - Market Cap to Projected Revenue|XRTX (XORTX) - Forward Price-to-Revenue Multiple|Vyome Therapeutics - Forward Price to Sales|Price-to-Projected Revenue Ratio Revelation Biosciences|Market Cap to Projected Revenue INDP (indaptusrx.com)|Forward Price-to-Revenue Multiple SCNI (Scinai Immunotherapeutics Ltd.)|Market Cap to Expected Sales Ratio calcimedica.com|Affimed N.V. - Forward Price-to-Revenue Multiple|Allakos Inc - Price-to-Projected Revenue Ratio|HOOK: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio IGM Biosciences, Inc. IGMS|ITOS: Forward P/S Multiple|OCEA - Market Cap to Expected Sales Ratio|TCBP (TC BioPharm (Holdings) PLC) - Forward P/S Multiple|Third Harmonic Bio Inc - Future Price to Revenue
